Featured Research Search Results
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)
Clinicaltrials.gov identifier:
NCT06844383
Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer
Study of the Drug Olvi-Vec in Women with Ovarian Cancer
Clinicaltrials.gov identifier:
NCT05281471
Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Sponsored By
